Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB / II study

Autor:	Catherine Diefenbach, James Essell, Ji Cheng, Andy I. Chen, Tycel Phillips, Franck Morschhauser, Mark Brunvand, David Ramies, Annalisa Chiappella, Ian W. Flinn, Jamie Hirata
Rok vydání:	2021
Předmět:	Oncology medicine.medical_specialty chemistry.chemical_compound chemistry Obinutuzumab business.industry Internal medicine Relapsed refractory medicine Hematology business Polatuzumab vedotin
Zdroj:	American Journal of Hematology. 97
ISSN:	1096-8652 0361-8609
DOI:	10.1002/ajh.26400
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::56fe92adb9b8728208ea0b85cb63ad05 https://doi.org/10.1002/ajh.26400 Zobrazit plný text záznamu Plný text